Should You Meet With FDA About Your Nonclinical Safety Data? By Dr. Bill F. Hodnick, DABT and Dr. Jerry Bettis, DABT Teams overseeing nonclinical studies often reach a point where the toxicology data raises more questions than ...
Uncategorized
FDA INTERACT Meetings: A Guide for Emerging Biotechs
How Emerging Biotechs Use FDA INTERACT Meetings to Avoid Costly Missteps By Lane Jaeckle Santos, Ph.D., RAC The most expensive FDA question is the one you ask too late. A biotech company can pivot after receiving an unexpected ...
gET sOCIAL